🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

70 results for “autologous” Clear

  1. Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)

    LISATA THERAPEUTICS, INC.

    Stage IV Melanoma

    phase 3 mab terminated

    1 trial

  2. Autologous Peripheral Blood Stem Cell injection

    Hospital Authority, Hong Kong

    Acute Myocardial Infarction

    phase 3 mab active

    1 trial

  3. Expanded autologous adipose-derived adult stem cells (eASCs)

    Takeda

    Complex Perianal Fistula

    phase 3 small molecule terminated

    1 trial

  4. Instant MSC Product accompanying Autologous Chondron Transplantation (IMPACT)

    Disc Medicine

    Symptomatic articular cartilage lesion of the knee (femoral condyles or trochlea)

    phase 3 small molecule active

    1 trial

  5. Suspension of autologous mononuclear cells separated from bone marrow aspirate

    The George Institute

    diabetic foot syndrome, lower limb ischemia

    phase 3 small molecule active

    1 trial

  6. eythrocytapheresis

    Atrium Therapeutics

    Pre Operative Autologous Donation

    phase 3 other completed

    1 trial

  7. A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis (KYSA-3)

    Kyverna Therapeutics

    Lupus Nephritis

    phase 2 other active

    1 trial

  8. AUTOLOGOUS DENDRITIC CELLS LOADED WITH AUTOLOGOUS TUMOR LYSATE, Tecentriq 1 200 mg concentrate for solution for infusion

    The George Institute

    Lung Cancer

    phase 2 small molecule active

    1 trial

  9. Autologous (self) mononuclear cells derived from umbilical cord blood

    Regeneron Ireland Designated Activity Company (DAC)

    Hypoplastic Left Heart Syndrome

    phase 2 mab active

    1 trial

  10. Autologous BCMA-targeting CAR T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma in Relapse

    phase 2 mab active

    1 trial

  11. Autologous Bone Marrow Mononuclear Cells

    Lxo Ireland Designated Activity Company

    Peripheral Vascular Diseases

    phase 2 other completed

    1 trial

  12. Autologous CD5 CAR T-cells

    The First People's Hospital of Lianyungang

    T-Cell Acute Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  13. Autologous CD5 CAR T-cells

    Universal Integrated

    T-Cell Acute Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  14. Autologous CD7 CAR T-cell

    Universal Integrated

    T-cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  15. Autologous Fat Transfer

    United Therapeutics Europe Ltd

    Wound

    phase 2 other completed

    1 trial

  16. Autologous Room Temperature stored Platelet transfusion

    United Therapeutics Europe Ltd

    Reversal of Platelet Aggregation Inhibitors

    phase 2 mab active

    1 trial

  17. Autologous Skin Fibroblasts

    United Therapeutics Europe Ltd

    Amputation

    phase 2 mab active

    1 trial

  18. Autologous Tumor Infiltrating Lymphocytes MDA-TIL

    Iovance Biotherapeutics B.V.

    Malignant Solid Neoplasm

    phase 2 mab terminated

    1 trial

  19. Autologous Volar Fibroblast Injection into the Terminal Limb of Amputees

    United Therapeutics Europe Ltd

    Amputation

    phase 2 other active

    1 trial

  20. Autologous adipose derived mesenchymal stem cells

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia (CLI)

    phase 2 small molecule completed

    1 trial

  21. Autologous bone marrow mononuclear cell transplantation

    EuroGen Pharmaceuticals Ltd

    Spinal Cord Injury

    phase 2 mab terminated

    1 trial

  22. Autologous hematopoietic stem cell infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prolonged Cytopenia Following CAR-T Therapy

    phase 2 mab active

    1 trial

  23. Autologous mesenchymal stem cells from adipose tissue.

    Lxo Ireland Designated Activity Company

    Autoimmune Diseases

    phase 2 other completed

    1 trial

  24. Bone marrow mesenchymal stem cells autologous

    Lxo Ireland Designated Activity Company

    Multiple Sclerosis

    phase 2 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources